0001415889-22-012966.txt : 20221223
0001415889-22-012966.hdr.sgml : 20221223
20221223162337
ACCESSION NUMBER: 0001415889-22-012966
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221221
FILED AS OF DATE: 20221223
DATE AS OF CHANGE: 20221223
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ni Fang
CENTRAL INDEX KEY: 0001895910
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 221485638
MAIL ADDRESS:
STREET 1: C/O BLACK DIAMOND THERAPEUTICS, INC.
STREET 2: ONE MAIN STREET, 10TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: ONE MAIN STREET, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
form4-12232022_091226.xml
X0306
4
2022-12-21
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001895910
Ni Fang
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 14TH FLOOR
CAMBRIDGE
MA
02142
false
true
false
false
SEE REMARKS
Common Stock
2022-12-21
4
P
0
20000
1.2885
A
89026
D
Common Stock
2022-12-22
4
P
0
36363
1.2814
A
125389
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.3099, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Officer Title: Chief Business Officer and interim Chief Financial Officer
Brent Hatzis-Schoch, as Attorney-in-Fact
2022-12-23